Although the lifetime risk of glucose intolerance and T2D in a number of conditions treated with GH, including Turner syndrome (TS) and in short children born SGA, is higher than in the background population, GH treatment does not increase the incidence of T2D in these conditions in the short term. Here, GH1 is linked to Glucose intolerance.